Stockscreener 앱 받기
58.65
0.88%
-0.52
시간 외 거래:
58.65
전일 마감가:
$59.17
열려 있는:
$58.49
하루 거래량:
1.35M
Relative Volume:
0.81
시가총액:
$11.44B
수익:
$2.75B
순이익/손실:
$322.29M
주가수익비율:
35.12
EPS:
1.67
순현금흐름:
$300.88M
1주 성능:
-1.71%
1개월 성능:
-17.67%
6개월 성능:
-16.55%
1년 성능:
-33.83%
1일 변동 폭
$58.29
$59.91
1주일 범위
$58.00
$60.93
52주 변동 폭
$52.93
$94.85
바이오마린 Stock (BMRN) Company Profile
명칭
Biomarin Pharmaceutical Inc
전화
(415) 506-6700
주소
105 DIGITAL DRIVE, NOVATO, CA
BMRN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
58.65 | 11.44B | 2.75B | 322.29M | 300.88M | 1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
바이오마린 Stock (BMRN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-24 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-30 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-20 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | 개시 | Evercore ISI | Outperform |
| 2023-11-15 | 개시 | Wells Fargo | Overweight |
| 2023-10-23 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | 개시 | Raymond James | Mkt Perform |
| 2023-09-18 | 개시 | UBS | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Perform |
| 2023-07-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-03-21 | 개시 | Bernstein | Underperform |
| 2023-02-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-02-21 | 개시 | Citigroup | Neutral |
| 2023-01-30 | 개시 | BMO Capital Markets | Market Perform |
| 2023-01-18 | 개시 | Canaccord Genuity | Hold |
| 2022-10-31 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-13 | 재개 | Wedbush | Neutral |
| 2022-04-25 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | 재개 | Jefferies | Buy |
| 2021-09-09 | 업그레이드 | Stifel | Hold → Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-04 | 재개 | Guggenheim | Buy |
| 2021-03-01 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-08-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-08-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2020-08-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | 재확인 | Citigroup | Buy |
| 2020-01-28 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-27 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-24 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Citigroup | Buy |
| 2019-04-09 | 재개 | Raymond James | Outperform |
| 2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-07 | 재확인 | Stifel | Buy |
| 2018-08-03 | 재확인 | Stifel | Buy |
모두보기
바이오마린 주식(BMRN)의 최신 뉴스
Oppenheimer maintains BioMarin stock Outperform with $98 target By Investing.com - Investing.com South Africa
Oppenheimer maintains BioMarin stock Outperform with $98 target - Investing.com
Joshua Grass, John Kelly, and Lauren Daniel Join 5AM Ventures - GlobeNewswire Inc.
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term - Yahoo Finance
BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET - Longview News-Journal
Spruce Pivots After Pipeline Failure With BioMarin Tralesinidase Deal - insights.citeline.com
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction - Benzinga
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q1 Release - Yahoo Finance
With BioMarin deal, Spruce Biosciences hits reset on rare-disease drugSan Francisco Business Times - The Business Journals
Spruce Biosciences Acquires Tralesinidase Alfa From BioMarin - marketscreener.com
Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Strength Seen in BioMarin (BMRN): Can Its 6.3% Jump Turn into More Strength? - Yahoo Finance
Astronics and Boston Beer have been highlighted as Zacks Bull and Bear of the Day - TradingView
Will Trump Tariffs Make or Break Healthcare Space? 3 Stocks to Rely On - Yahoo Finance
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025 - Yahoo Finance
What Makes BioMarin (BMRN) a New Buy Stock - Yahoo Finance
BMRN vs. CSLLY: Which Stock Is the Better Value Option? - Yahoo Finance
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance
BMRN stock touches 52-week low at $60.63 amid market shifts - Investing.com Canada
BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study - MSN
BioMarin succeeds in trial for its metabolic disorder treatment - MSN
Edmond DE Rothschild Holding S.A. Boosts Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical: Pegasus Success May Lead To Palynziq Label Expansion (BMRN) - Seeking Alpha
Nomura Asset Management Co. Ltd. Sells 73,310 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin’s trial for phenylketonuria therapy meets primary efficacy endpoint - Yahoo Finance
The Top 12 Companies Hiring in Biopharma Now - BioSpace
BioMarin (BMRN) Advances PALYNZIQ in Key Late-Stage Trial for PK - GuruFocus
BioMarin’s PALYNZIQ shows promise for adolescents with PKU - Investing.com India
BioMarin’s PALYNZIQ shows promise for adolescents with PKU By Investing.com - Investing.com South Africa
BioMarin Seeks Label Expansion For Palynziq After Positive Phase 3 Results In Adolescent Patients - Yahoo
BioMarin's Trial for Phenylketonuria Shows Palynziq Reduces Blood Phenylalanine in Adolescents - MarketScreener
Is BioMarin Pharmaceutical Inc. (BMRN) The Most Profitable Biotech Stock To Buy Right Now? - MSN
Is Royalty Pharma plc (RPRX) The Most Profitable Biotech Stock To Buy Right Now? - Yahoo Finance
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock - Yahoo Finance
BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales - MSN
BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria - PR Newswire
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
The Price Is Right For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - simplywall.st
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
US FDA approves Sanofi's bleeding disorder therapy - MarketScreener
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock - Yahoo Finance
Pharma Boom: BioMarin’s Surprising Surge - timothysykes.com
Is BioMarin Pharmaceutical Inc. (BMRN) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Holdings Lifted by Sector Gamma AS - MarketBeat
Insider Sell Alert: Erin Burkhart Sells Shares of Biomarin Pharm - GuruFocus
BioMarin (BMRN) Up 4.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - Yahoo Finance
Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN) - Yahoo Finance
바이오마린 (BMRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.15%
4.32%
자본화:
|
볼륨(24시간):